Tango Therapeutics Stock Market Value
| TNGX Stock | USD 24.20 1.49 6.56% |
| Symbol | Tango |
Earnings Share -0.94 | Revenue Per Share | Quarterly Revenue Growth -100.0% | Return On Assets | Return On Equity |
Tango Therapeutics' market capitalization and book value each provide useful but distinct information about the business. Tango Therapeutics' market capitalization is 3.28 billion. Tango Therapeutics P/B of 8.74 reflects a market valuation far exceeding accounting equity. Enterprise value (TTM) stands at 2.96 billion. The relationship between Tango Therapeutics' intrinsic value, market price, and book value adds depth to the analysis.
Value and price for Tango Therapeutics may converge over time but can differ substantially in any given period. For Tango Therapeutics, key inputs include a P/B ratio of 8.74, a profit margin of -1.71%, ROE of -31.0%, and revenue of 62.38 million.
What-If Analysis
Backtesting a what-if scenario on Tango Therapeutics shows how the stock may have behaved if the position had been entered, held, or resized under different historical assumptions. Comparing realized return, risk, and path dependency instead of focusing only on the best historical outcome gives a more complete picture.
| 02/04/2026 |
| 05/05/2026 |
Investing 0.00 in Tango Therapeutics starting February 4, 2026 and holding to today would realize 0.00 in aggregate gains. That works out to a 0.0% total return in Tango Therapeutics in total over a 90 day period. Tango Therapeutics is grouped with peers such as Septerna Common, UroGen Pharma, ProKidney Corp, Eyepoint Pharmaceuticals, Bicara Therapeutics, Kodiak Sciences, and Kura Oncology based on business similarity. Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer More
Tango Therapeutics Momentum Range Indicators Snapshot
For Tango Therapeutics, these indicators describe the distribution of price movement across recent upside and downside ranges. Readings near range extremes can signal stretched momentum conditions.
| Downside Deviation | 3.92 | |||
| Information Ratio | 0.1936 | |||
| Maximum Drawdown | 48.53 | |||
| Value At Risk | -4.89 | |||
| Potential Upside | 8.25 |
Market Risk Indicators for Tango Therapeutics Signals
Tango Therapeutics market risk signals reflect the scope and pattern of historical return variability. Value-at-risk estimates translate volatility into a probability-weighted loss threshold for a given confidence level.| Risk Adjusted Performance | 0.1939 | |||
| Jensen Alpha | 1.17 | |||
| Total Risk Alpha | 1.23 | |||
| Sortino Ratio | 0.3003 | |||
| Treynor Ratio | 20.53 |
Mean reversion is the tendency of Tango Therapeutics' price to return to its historical average after periods of extreme deviation. Some analysts monitor this tendency by comparing Tango Therapeutics' price extremes to fundamental value.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1939 | |||
| Market Risk Adjusted Performance | 20.54 | |||
| Mean Deviation | 3.79 | |||
| Semi Deviation | 3.3 | |||
| Downside Deviation | 3.92 | |||
| Coefficient Of Variation | 516.25 | |||
| Standard Deviation | 6.08 | |||
| Variance | 37.0 | |||
| Information Ratio | 0.1936 | |||
| Jensen Alpha | 1.17 | |||
| Total Risk Alpha | 1.23 | |||
| Sortino Ratio | 0.3003 | |||
| Treynor Ratio | 20.53 | |||
| Maximum Drawdown | 48.53 | |||
| Value At Risk | -4.89 | |||
| Potential Upside | 8.25 | |||
| Downside Variance | 15.38 | |||
| Semi Variance | 10.92 | |||
| Expected Short fall | -4.76 | |||
| Skewness | 2.89 | |||
| Kurtosis | 16.56 |
Tango Therapeutics Backtested Returns
Tango Therapeutics currently shows a stable performance profile across the evaluation window. It has a Sharpe Ratio of 0.2, evidencing risk-calibrated returns. We identified twenty-nine technical indicators influencing the company's volatility profile. Please assess metrics such as Coefficient Of Variation of 516.25, semi deviation of 3.3, and risk-adjusted performance of 0.1939 to validate implied volatility levels. Tango Therapeutics holds a performance score of 15 on a scale of zero to a hundred. The firm retains a Market Sensitivity (Beta) of 0.0569, which indicates very low measured sensitivity to broad market movements. Returns on Tango Therapeutics tend to trail the broader market in strong rallies but hold up better when sentiment turns negative.
Auto-correlation | 0.35 |
Below average predictability
Tango Therapeutics shows below average predictability when comparing price series from 4th of February 2026 to 21st of March 2026 against from 21st of March 2026 to 5th of May 2026. A strong serial relationship would imply that Tango Therapeutics's recent trajectory contains information about its near-term direction. With a serial correlation of 0.35, nearly 35.0% of Tango Therapeutics's price variation is attributable to patterns in preceding intervals.
| Correlation Coefficient | 0.35 | |
| Spearman Rank Test | 0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 7.5 |